RxDoctor Payments Data

Ryan Evans

Optometrist · Murrieta, CANPI 1548575111

Payments from drug & device makers

$1,798in general payments, 2019–2025

Across 32 payments — averaging $56.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$415
  • Dompe US, Inc.$339
  • AbbVie$207
  • Glaukos Corporation$159
  • Oyster Point Pharma, Inc.$154
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$124
  • plus $399 from 6 others

What the payments were for

  • Food & beverage$1,72899%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,798 in reported general payments places this provider in the 75th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$33,376
Medicare patients
198
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine185$131,203
Cyclosporine170$51,625
LumiganBimatoprost50$23,989
XiidraLifitegrast17$17,214
RocklatanNetarsudil Mesylat/Latanoprost35$12,697
RhopressaNetarsudil Mesylate14$8,794
Latanoprost590$5,167
Alphagan PBrimonidine Tartrate16$4,902
Brimonidine Tartrate119$4,623
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$3,013
Travoprost17$2,852
Brinzolamide12$2,461
Prednisolone Acetate88$2,238
Dorzolamide Hcl75$1,369
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$207$160,094251 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$90$21,49149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,778 optometrist providers in California.

Other optometrist in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →